Rifampicin 300 mg Section 19A Approval – Now Available from Pro Pharmaceuticals Group

Dear Healthcare Professional,

Shortage of RIFADIN (Rifampicin 300 mg capsules) – AUST R: 22030

Pro Pharmaceuticals Group acknowledges the ongoing national shortage of RIFADIN (Rifampicin 300 mg capsules, AUST R: 22030), a frontline antibiotic used in the treatment of tuberculosis and other serious bacterial infections.

To support continued patient care and minimise treatment disruptions, Pro Pharmaceuticals Group has secured supply of an alternative product – Rifampin (Rifampicin) 300 mg Capsules USP from Lupin Pharmaceuticals, USA.

This product is not registered in Australia but has been approved for supply under TGA Section 19A until 31 March 2026, in accordance with the Therapeutic Goods Act 1989. It is available in both:

• 60-capsule bottles, and

• 30-capsule bottles

  
  

This Rifampicin 300 mg Section 19A approval ensures ongoing access for hospitals and TB programs nationally.

We encourage hospital pharmacies, infectious diseases units, and central pharmacy procurement teams to share this information internally and contact us regarding supply.

📧 For orders or further enquiries, please email: orders@propg.com.au🌐 Or visit: www.propg.com.au